# Population

## Describe the population in which the proposed health technology is intended to be used:

The population that relates to this application are patients who receive a bioinductive collagen implant (BCI) (REGENETEN™), used with surgical repair, who have symptomatic rotator cuff tears of the shoulder. Specifically, there are two subpopulations which can be grouped by depth of the rotator cuff tear:

* Subpopulation 1: Patients with symptomatic partial-thickness rotator cuff tear (PTRCT) where there is no substantial loss of tissue who have failed at least three months of conservative (non-surgical) management and are considered eligible for (or indicated for) surgical repair.
* Subpopulation 2: Patients with symptomatic full-thickness rotator cuff tear (FTRCT) where there is no substantial loss of tissue who have failed at least three months of conservative (non-surgical) management and are considered eligible for (or indicated for) surgical repair.

## Specify any characteristics of patients with the medical condition, or suspected of, who are proposed to be eligible for the proposed health technology, describing how a patient would be investigated, managed and referred within the Australian health care system in the lead up to being considered eligible for the technology:

The population that relates to the Prostheses List request are patients who receive a bovine bioinductive collagen implant (BCI) (REGENETEN™), used with surgical repair, who have symptomatic rotator cuff tears of the shoulder. Specifically, there are two subpopulations which can be grouped by depth of the rotator cuff tear:

* Subpopulation 1: Patients with symptomatic partial-thickness rotator cuff tear (PTRCT) where there is no substantial loss of tissue who have failed at least three months of conservative (non-surgical) management and are considered eligible for (or indicated for) surgical repair.
* Subpopulation 2: Patients with symptomatic full-thickness rotator cuff tear (FTRCT) where there is no substantial loss of tissue who have failed at least three months of conservative (non-surgical) management and are considered eligible for (or indicated for) surgical repair.

The distinction of these two patient subgroups is important, given current approaches to surgical management differ, based on if the tear is partial or full-thickness (and among other variables).

In addition, it is proposed that, in order to access this treatment, patients should not have responded to conservative (i.e. non-surgical) management, including pain relief (e.g. nonsteroidal anti-inflammatory medication (NSAIDs) ± corticosteroid injections), modified daily activities and physical therapy (e.g. physiotherapy) for at least three months. *This was similar to the definition applied in the early feasibility Australian studies by Bokor et al. (1, 2).*

The clinical workup includes documenting patient history and symptoms (mobility, stability, pain, strength) patient characteristics and biological factors that may affect healing (particularly age, smoking, diabetes, autoimmune disease, social and occupational context), and establishing the morphological features of the tear by physical examination and medical imaging (3).

The Applicant indicated that REGENETEN™ is not intended to be used in acute trauma.

## Provide a rationale for the specifics of the eligible population:

The rotator cuff provides glenohumeral joint stability (3). It is a group of four muscles and their tendons (supraspinatus, infraspinatus, teres minor, and subscapularis) at the shoulder joint which form a multilayered horseshoe shape cuff around the head of the humorous bone (4). Each tendon has a separate footprint with a wide range of widths and lengths (range medial to lateral: 12-33mm; range anterior to posterior: 15-55mm; Table 1.

Table  - Rotator cuff tendon dimensions

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Rotator cuff tendon** | **Medial to lateral** | **width** | **Anterior to posterior** | **width** |
| **Mean (mm)** | **Range (mm)** | **Mean (mm)** | **Range (mm)** |
| Supraspinatus | 16 | 12-20 | 23 | 18-33 |
| Infraspinatus | 18 | 12-24 | 28 | 20-45 |
| Teres minor | 21 | 10-33 | 29 | 20-40 |
| Subscapularis | 20 | 15-25 | 40 | 35-55 |

Source: Table 1 of Matthewson 2015 (5)

Rotator cuff injury can range from simple inflammation to tears of the muscles or tendons. Rotator cuff tears may result due to a degeneration of the tendon quality or due to trauma, where a tear arises from a major injury to otherwise healthy tissue. Most tears are degenerative tears and are due to the progression of chronic tendonitis[[1]](#footnote-2), which may or may not be symptomatic (3). However, rotator cuff tears that occur as a result of trauma, are rare in young patients (age<35 years) (6). Several risk factors have been identified in predisposing individuals to the development of rotator cuff tears; increasing patient age, smoking, hypercholesterolemia, and family history. The Applicant stated that each of these may play an additive role to the underlying influence of age- related degeneration in the development of rotator cuff disease.

Subpopulation 1:

PTRCTs do not extend through the full-thickness of the tendon. They can involve any of the four rotator cuff tendons and are typically classified by location: articular sided, bursal side, or intratendinous (which are only seen on imaging) (7). Subclassification includes the size, or depth of the tear, which can be represented as percentage of the tendon thickness torn. The Ellman classification system (8) classifies PTRCTs by determining the amount of exposed articular footprint. Specifically, Grade I (*low*): < 3mm (<25% tendon thickness); Grade II (*medium*): 3-6mm (25-50% tendon thickness); and Grade III (*high*): >6mm (>50% tendon thickness, but not full-thickness); Table 2) (5, 7). While widely accepted, this classification system does not take into account a number of factors including: an analysis of tissue quality, the area of tearing (i.e., not just thickness but anterior to posterior and medial to lateral), or the aetiology of the tear itself (5). In addition, controversy exists around the amount of footprint needed for a tear to be classified as a 50% partial- thickness tear (7).

Table - Classification of PTRCTs: articular, bursal and intratendinous locations

|  |  |  |
| --- | --- | --- |
| **Grade** | **Size of tear** | **Percentage of tendon thickness** |
| I | <3mm | <25% |
| IIa | 3-6mma | 25-50% |
| IIIb | >6mmb | >50% (but less than full thickness) |

Source: Table 2 of Matthewson 2015 (5)

Abbreviations: PTRCT = partial-thickness rotator cuff tear

a Classified as intermediate in Bokor 2016 (2)

b Classified as high in Bokor 2016 (2)

The current Australian evidence base (Bokor et al (1, 2)) for bovine BCI in subpopulation 1 is in patients with symptomatic ≥ Grade II (>25% tendon thickness) PTRCTs (see Table 3 (attached as appendix)). PASC noted that patients with grade 1 PTRCTs would not be eligible for REGENETEN, as they are usually asymptomatic.

The Applicant stated that the literature demonstrates that articular‐sided tears, which can be subclassified as partial articular sided rotator cuff tears (PASTA), are at least twice as common as bursal‐sided tears, and that most tears involve the supraspinatus tendon (9). The current Australian evidence base (Bokor et al (1, 2)) for the proposed intervention is exclusively in supraspinatus tears (PTRCT and FTRCT; see Table 3 (attached as appendix)). The Applicant would like to highlight that Bokor et al (1, 2) were early feasibility studies; since the original 1593 Application, updated published literature in the form of randomised controlled trials, case series and, real-world evidence (registries and retrospective comparative analyses) are now available to provide long-term follow up evidence for the proposed intervention. Partial-thickness tears are 2-3 times more likely, connected to the bone. It is difficult to determine a consensus on the prevalence split between PTRCT and FTRCT, however, an Australian cohort study has identified a patient split of 39% PTRCT compared to 61% FTRCT (11); additionally, a significant proportion of PTRCTs eventually develop into FTRCT, potentially worsening the pre-existing symptoms (12, 13).

The spontaneous healing of untreated rotator cuff tears is rare (14-16) and without intervention, a partial-thickness tear is likely to enlarge and propagate into full-thickness tears (17, 18). Progression of symptomatic partial-thickness tears to full-thickness tears with non‐operative treatment has been seen in 18% of patients followed up for over 1 year, with a further 34% exhibiting increase in partial tear size (19). Because increased tear size and poorer muscle quality are associated with poorer healing after surgical repair, repair before progression may improve outcomes (16). The risk of tear progression has been shown to correlate with percentage tendon thickness at presentation with progression observed in 55% of patients with ≥ 50% tearing of tendon thickness at presentation compared to 14% tear progression in those who had < 50% tearing (5, 20).

Subpopulation 2:

FTRCTs involve the full detachment of a length of the tendon that attaches the muscles from the shoulder blade to the head of the humerus. They can be classified by the DeOrio and Cofield classification system (21), which classifies FTRCT as either small (< 1cm), medium (1-3cm), large (3- 5cm) and massive (>5cm)2. However, some prefer to classify a massive tear as involving two or more tendons; usually the supraspinatus and infraspinatus, but also supraspinatus and subscapularis (6).

The current Australian evidence base (Bokor et al (1, 2)) for bovine BCI in subpopulation 2 is in patients with symptomatic [chronic shoulder pain ≥3months] medium (1-3cm) FTRCTs. However, it was noted in a recent US study (Thon et al 2019 (22)) that bovine BCI was applied to a population with more advanced disease severity: patients with symptomatic large and massive (>3cm and minimum 2-tendon involvement) FTRCTs (see Table 3 appendix). PASC queried the 3- month wait for the FTRCT population, as it would seem unlikely this population would wait 3 months before a surgical procedure. PASC confirmed this would be rare, but accepted the population 2 description should remain as is.

# Intervention

## Name of the proposed health technology:

## REGENETEN Bioinductive Implant for the repair of rotator cuff tear

## Describe the key components and clinical steps involved in delivering the proposed health technology:

The procedure is performed under general anaesthesia (2) in the hospital inpatient setting (private and public), with overnight hospitalisation. The procedure can be performed arthroscopically (minimally invasive keyhole surgery) or as mini-open surgery (which involves a small incision typically 3 to 5 cm long). The Applicant stated that arthroscopic and mini-open repair surgical techniques are associated with similar outcomes, with both being able to be used interchangeably, depending on patient and rotator tear characteristics (23, 24). This is similar to recommendations in the *I.S.Mu.L.T ‘Rotator Cuff Tear Guidelines’* which state there are no statistically significant differences between the two techniques, in terms of relapse, complications and functional outcomes (25).

The Applicant advised, based on expert opinion and case study reference, that the average time to implant the REGENETEN system is 10 minutes (26) and depends on the learning curve of the surgeon. However, for **subpopulation 1,** REGENETEN is implanted in phase three of the surgical repair procedure in lieu of implanting suture anchors (as standard surgical repair with sutures or anchors is not required in this population); and for **subpopulation 2** REGENETEN is implanted in phase four of the surgical repair procedure in addition to implanting suture anchors (as surgical repair with sutures or anchors is required in addition to bovine BCI). *If surgical repair was performed, this was immediately prior to applying bovine BCI* (1, 22). The Applicant’s summary of the phases required for surgery in each subpopulation is provided in Table 4.

Table 4 - Description of surgical procedures with use of bovine BCI in both populations

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Subpopulation 1** | **Incremental Procedure time** | **Subpopulation 2**  | **Incremental Procedure time** |
| Phase 1 | Anaesthesia and skin penetration | - | Anaesthesia and skin penetration |  |
| Phase 2 | Debridement, diagnosis and bursectomy | - | Debridement, diagnosis and bursectomy |  |
| Phase 3 | Arthroscopic surgical repair with REGENETEN | N/A REGENETEN is implanted (10 mins) in lieu of suture anchors and thus there is no incremental procedural time | Standard arthroscopic or mini-open surgical repair (Sutures or anchors)a |  |
| Phase 4 | N/A | N/A | Arthroscopic surgical repair with REGENETEN | 10 minutes (26, 57) |

Source: Applicant feedback N/A = not applicable

a As per comparator; refer to comparator section for description of these surgical procedures

The Applicant stated that for both subpopulations, the proposed intervention is intended to be performed once.

The procedure is performed by orthopaedic surgeons. *The Applicant and its nominated clinical expert confirmed at PASC that no additional training is required by orthopaedic surgeons to use REGENETEN in appropriate patients. However, this should be verified during the assessment phase.*

The Applicant also provided the detailed surgical steps in arthroscopic use of REGENETEN™ (as published in Wasburn et al. 2017 (17) (see below) and provided this schematically in Figure 1.

1. Diagnostic arthroscopy is performed.
2. Tendon markers along the anterior edge of the supraspinatus are placed in a percutaneous fashion.
3. Entry is made into the subacromial space, and bursectomy is performed through a standard lateral portal.
4. A 5-mm guidewire is placed at the lateral edge of the rotator cuff footprint.
5. The graft is hydrated (in saline) for one minute
6. The graft is loaded into the delivery instrument.
7. The graft is introduced until the red button becomes prominent.
8. The graft is deployed.
9. A second lateral cannula is placed just off the lateral edge of the acromion.
10. Soft-tissue staples are placed through the graft into the underlying rotator cuff.
11. The tendon markers are removed.
12. A bone stapler awl is used to tension the graft from the lateral portal.
13. The bone staples are placed.
14. The instruments are removed, and the wounds are closed [Application Form, p12]

|  |
| --- |
| Figure 1 - Application of bovine BCI (using REGENTEN™ |
|  Application of bovine BCI (using REGENTEN™)  Figures displaying the application of REGENETEN |
| Source: Applicant feedback (27)Legend: A. Bioinductive Implant Placement Cannula insertion; B. Bioinductive Implant Placement deployment; C. Tendon Anchor insertion at medial edge; D. Completed Tendon Anchor insertion at posterior and anterior edges; E. Bone Anchor insertion at lateral edge; F. Fully fixated REGENTEN Bioinductive implant |

## Identify how the proposed technology achieves the intended patient outcomes:

The REGENETEN implant, when used in isolation (partial-thickness tears) or as an adjunct to a mechanical repair (full-thickness tears), provides a porous scaffold for the formation of new tendon-like tissue. REGENETEN supports the body’s natural healing response to facilitate new tendon-like tissue growth and change the course of rotator cuff tear progression. As the newly formed tissue begins to take up more local stress, a natural cell-based remodelling of the extracellular matrix occurs, and the implant is resorbed within six months (28). The load sharing abilities of the new tendon-like tissue decreases the strain in the native tendon to allow for tendon healing and functional gains (29). REGENETEN is positioned arthroscopically, tendon and bone staples secure the scaffold in place while the new tissue is being generated. The procedure is performed under general anaesthesia and may be performed by mini-open surgery (30).

## Does the proposed health technology include a registered trademark component with characteristics that distinguishes it from other similar health components?

 Yes

## Explain whether it is essential to have this trademark component or whether there would be other components that would be suitable:

The proposed medical service, bioinductive collagen implant does include a registered trademark component, REGENETEN™, which is a bovine collagen implant available in Australia.

## Are there any proposed limitations on the provision of the proposed health technology delivered to the patient (For example: accessibility, dosage, quantity, duration or frequency): (please highlight your response)

No

## Provide details and explain:

There are no apparent constraints in the health care system that would impact on uptake.

There are no current limitations on provision of the proposed medical service, with respect to accessibility.

## If applicable, advise which health professionals will be needed to provide the proposed health technology:

The procedure is performed by orthopaedic surgeons. The Applicant and its nominated clinical expert confirmed at PASC that no additional training is required by orthopaedic surgeons to use REGENETEN in appropriate patients. However, this should be verified during the assessment phase.

## If applicable, advise whether delivery of the proposed health technology can be delegated to another health professional:

N/A

## If applicable, advise if there are any limitations on which health professionals might provide a referral for the proposed health technology:

Referral to an orthopaedic surgeon for further review and possible surgical repair of the tear is indicated when symptoms fail to improve following a minimum of 3 months of conservative treatment, or where a tear has occurred from sudden trauma or acute injury and is impacting on comfort and function.

## Is there specific training or qualifications required to provide or deliver the proposed service, and/or any accreditation requirements to support delivery of the health technology?

No

## Provide details and explain:

N/A

Indicate the proposed setting(s) in which the proposed health technology will be delivered:

[ ]  Consulting rooms

[x]  Day surgery centre

[ ]  Emergency Department

[x]  Inpatient private hospital

[x]  Inpatient public hospital

[ ]  Laboratory

[ ]  Outpatient clinic

[ ]  Patient’s home

[ ]  Point of care testing

[ ]  Residential aged care facility

[ ]  Other (please specify)

## Is the proposed health technology intended to be entirely rendered inside Australia?

Yes

## Please provide additional details on the proposed health technology to be rendered outside of Australia:

N/A

# Comparator

## Nominate the appropriate comparator(s) for the proposed medical service (i.e. how is the proposed population currently managed in the absence of the proposed medical service being available in the Australian health care system). This includes identifying health care resources that are needed to be delivered at the same time as the comparator service:

## Please provide a name for your comparator:

Standard surgical repair (take-down and repair - i.e. suture anchors alone, without use of bovine BCI).

## Please provide an identifying number for your comparator (if applicable):

N/A

## Please provide a rationale for why this is a comparator:

Simple arthroscopic debridement (with or without subacromial decompression) could be a comparator for some patients with symptomatic PTRCT < 50% tendon thickness (or Ellman Grade II or less), and for patients with symptomatic FTRCTs that are not amenable to direct repair. FTRCTs that are considered not amenable to direct repair are tears that are not reducible without tension or tears with > stage 2 fatty degeneration (3).

Prosthetic surgery (e.g. humeral prosthesis or a total reversed prosthesis) is also an option for a patients with (index) shoulder with co-existing rotator cuff arthropathy (e.g. rotator cuff tear with joint disease, such as arthritis) and pseudo-paralytic symptoms due to a massive rotator cuff tear. However, a prosthesis is only indicated if all other treatment options have been exhausted (3).

## Pattern of substitution – Will the proposed health technology wholly replace the proposed comparator, partially replace the proposed comparator, displace the proposed comparator or be used in combination with the proposed comparator? (please select your response)

[ ]  None *(used with the comparator)*

[ ]  Displaced *(comparator will likely be used following the proposed technology in some patients)*

[x]  Partial *(in some cases, the proposed technology will replace the use of the comparator, but not in all cases)*

[ ]  Full *(subjects who receive the proposed intervention will not receive the comparator)*

## Please outline and explain the extent to which the current comparator is expected to be substituted:

Subpopulation 1:

It is proposed that use of bovine BCI would be an alternative treatment option to standard surgical repair of symptomatic PTRCTs. Specifically, it would be provided in lieu of suture anchor repair alongside debridement and bursectomy, performed as part of standard surgical repair of PTRCTs.

PASC noted REGENETEN replaces the need for trans-tendon repair and take-down repair (i.e. standard surgical repair) for patients with a PTRCT. However, it does not replace the need for debridement and bursectomy (i.e. REGENETEN is performed in addition to debridement and bursectomy).

The surgical options for symptomatic PTRCTs are non-repair surgery, or debridement[[2]](#footnote-3) (i.e. smooth the tendon tear), and surgical repair. These procedures may be carried out alone or together, and should always be performed arthroscopically (3). *However, patients with symptomatic PTRCTs typically are expected to require standard repair surgery, using sutures or anchors.*

Specifically, the Applicant stated that standard surgical treatment for PTRCTs has evolved from simple arthroscopic debridement to surgical repair procedures, which there are two techniques:

* Trans-tendon repair; and
* Take-down and repair (7).

The trans-tendon repair involves maintaining the intact lateral portion of the tendon while repairing the medial aspect of the tendon. Following this, standard rotator cuff repair is performed using anchors and sutures. Theoretical benefits of a trans-tendon repair include anatomic restoration of the footprint and maintenance of the normal intact lateral cuff, which may improve biological or biomechanical characteristics and enhance healing (31).

The take-down and repair procedure involves artificially completing the tear during the surgery followed by standard rotator cuff repair using anchors and sutures (31). Although some surgeons advocate this technique, there is a reported failure rate of up to 18% (33). In addition, post- operative care is typically longer with this method (relative to trans-tendon technique) and may include six weeks of shoulder immobilisation (e.g. in sling) and rehabilitation over six months (33).

Specifically, for patients with articular-sided PTRCT, it is suggested both standard surgical repair procedures should be considered when the tear depth > 50% tendon thickness (7) (or Grade III according to Ellman).

The *I.S.Mu.L.T ‘Rotator Cuff Tear Guidelines’* state that arthroscopic debridement with or without acromioplasty, and the surgical repair techniques (transtendinous or “completion and repair [i.e. take-down and repair]” technique) are the most frequent treatments for PTRCTs. However, these Guidelines advise that current evidence is low level, which does not allow determination of best treatment (25).

Subpopulation 2:

The Applicant has proposed that the use of bovine BCI would be in addition (i.e. add on service) to surgical repair for symptomatic FTRCTs (subpopulation 2) [Application form, p15], which require the use of standard sutures or anchors.

Standard surgical treatment for symptomatic FTRCTs is performed arthroscopically or as ‘mini-open’ surgery, and involves reattaching the muscle to the bone using standard sutures or anchors.

Prognostic factors, identified from case-series studies, have indicated the following outcomes following FTRCT surgery:

* Univariate analyses: Higher rate of secondary tearing AND/OR poorer clinical outcomes after repair by arthroscopy or open surgery are associated with the following:
	+ Extent of tear (extension to infraspinatus muscle);
	+ Tendon retraction;
	+ Decrease in pre-operative subacromial height on X-ray;
	+ Extensive fatty degeneration (assessed by computed tomography (CT) scan); and
	+ Occupation.
* Multivariate analyses: Main negative prognostic factors for direct open repair of FTRCTs are long standing pre-operative signs, poor general health, former or current smoker (>40 pack- years) and a large tear (≥ 5cm2) found during the procedure. Furthermore a tear of the subscapularis can be a negative prognostic factor for postoperative recovery (3).

Suturing

All rotator cuff tears (arthroscopic or mini-open) are surgically repaired with standard sutures or anchors. There are several techniques:

* Single-row: most common technique but reported high, up to 90% failure rates in case of large and massive injuries; and
* Double-row[[3]](#footnote-4): more resistant than single-row, but will impart greater strain on repaired tendon (25).

A 2013 meta-analysis of randomised controlled trials showed similar rates of re-tear using single- and double-row suture techniques (32).

# Outcomes

Overall

List the key health outcomes (major and minor – prioritising major key health outcomes first) that will need to be measured in assessing the clinical claim for the proposed medical service/technology (versus the comparator):

[x]  Health benefits

[x]  Health harms

[x]  Resources

## Outcome description – please include information about whether a change in patient management, or prognosis, occurs as a result of the test information:

Current treatment options for RCT include conservative and surgical repair (standard arthroscopic surgical repair) that do not address factors that lead to progression of degenerative disease. The introduction of REGENETEN to the RCT patient management algorithm will provide clinicians with an alternative or adjunct to standard arthroscopic surgical repair (take-down or trans-tendon in PTRCT, or sutures or anchors in FTRCT) that improves the quality of outcomes for patients with RCTs, whilst simultaneously reducing the economic burden to the health system and broader economy from lost productivity. For PTRCT, when REGENETEN Implant use is deemed appropriate, the remaining footprint of the tendon is preserved and healing potential will be provided by only REGENETEN. By replacing the invasive take-down and repair technique with isolated REGENETEN use, this new surgical option will provide access to an accelerated rehabilitation program which results in lower pain and a faster return of function (34). The ability to increase function and decrease pain also influences overall physical and mental health as measured by the VR-12 (34).

For FTRCT, Using REGENETEN as an adjunct to the suture anchor repair has been shown to decrease the risk of retear following repair, therefore, minimizing the number of surgical interventions required for rotator cuff pathology (35).

The introduction of REGENETEN, satisfies the following unmet needs:

* The need for a surgical solution for rotator cuff disease, that better preserves the natural anatomy of the shoulder joint to provide better patient recovery, including faster relief from pain, improvements in function, and return to an independent and active lifestyle
* The need for a technology that can facilitate the formation of new tendon-like tissue and demonstrate a reduced risk of postoperative re-tears.
* The need for a technology that can result in a faster recovery and low risk of re-tearing. This can be expected to promote earlier return to work, improve productivity, and reduce workers compensation payouts, resulting in a wider societal benefit.

Clinical Effectiveness Outcomes
List the key health outcomes (major and minor – prioritising major key health outcomes first) that will need to be measured in assessing the clinical claim for the proposed medical service/technology (versus the comparator):

[x]  Health benefits

[ ]  Health harms

[x]  Resources

## Outcome description – please include information about whether a change in patient management, or prognosis, occurs as a result of the test information:

A change in patient management and prognosis is expected as a result of the test information.

Clinical Effectiveness Outcomes

*Functional outcomes*

* + American Shoulder and Elbow Surgeons standardized Form for the Assessment of the Shoulder (ASES)
	+ Constant-Murley shoulder score
	+ Oxford Shoulder Score (OSS)
	+ VAS pain
	+ Post-operative physical therapy
	+ Post-operative return to activities
	+ Single Assessment Numeric Evaluation (SANE)
	+ Adverse Events
	+ Progression to full-thickness tear (if subpopulation 1); outcome reported in NCT03734536 (43)
	+ Western Ontario Rotator Cuff (WORC) index

Secondary effectiveness outcomes

List the key health outcomes (major and minor – prioritising major key health outcomes first) that will need to be measured in assessing the clinical claim for the proposed medical service/technology (versus the comparator):

[x]  Health benefits

[ ]  Health harms

[x]  Resources

## Outcome description – please include information about whether a change in patient management, or prognosis, occurs as a result of the test information:

A change in patient management and prognosis is expected as a result of the test information.

Secondary effectiveness outcomes

* + Length of hospital stay
	+ Time to return to work (to be included in resubmitted ADAR)

Safety

List the key health outcomes (major and minor – prioritising major key health outcomes first) that will need to be measured in assessing the clinical claim for the proposed medical service/technology (versus the comparator):

[ ]  Health benefits

[x]  Health harms

[x]  Resources

## Outcome description – please include information about whether a change in patient management, or prognosis, occurs as a result of the test information:

A change in patient management and prognosis is expected as a result of the test information.

Safety

* + Procedural complications
	+ Longer-term adverse events
	+ Revision surgery

Quality of Life

List the key health outcomes (major and minor – prioritising major key health outcomes first) that will need to be measured in assessing the clinical claim for the proposed medical service/technology (versus the comparator):

[x]  Health benefits

[ ]  Health harms

[x]  Resources

## Outcome description – please include information about whether a change in patient management, or prognosis, occurs as a result of the test information:

A change in patient management and prognosis is expected as a result of the test information.

Quality of Life

* + EuroQol-five dimension scale (EQ-5D)
	+ Short Form-36 Health Survey (SF-36)

## List the key health outcomes (major and minor – prioritising major key health outcomes first) that will need to be measured in assessing the clinical claim for the proposed medical service/technology (versus the comparator):

[x]  Health benefits

[x]  Health harms

[x]  Resources

## Outcome description – please include information about whether a change in patient management, or prognosis, occurs as a result of the test information:

A change in prognosis is expected as a result of the test information.

Imaging-based outcomes

* + Tendon thickness
	+ Size of the cuff defect (tear size, re-tear rate)

Cost-effectiveness

List the key health outcomes (major and minor – prioritising major key health outcomes first) that will need to be measured in assessing the clinical claim for the proposed medical service/technology (versus the comparator):

[x]  Health benefits

[ ]  Health harms

[x]  Resources

## Outcome description – please include information about whether a change in patient management, or prognosis, occurs as a result of the test information:

A change in patient management and prognosis is expected as a result of the test information.

Cost-effectiveness

* + Resource utilisation (surgical costs, diagnostic test, follow-up physiotherapy rehabilitation, pain management medication, and indirect costs (e.g. work days lost)
	+ Cost per life year gained, cost per quality-adjusted life year (QALY) gained, and incremental cost-effectiveness ratio.

Financial implications

List the key health outcomes (major and minor – prioritising major key health outcomes first) that will need to be measured in assessing the clinical claim for the proposed medical service/technology (versus the comparator):

[x]  Health benefits

[ ]  Health harms

[x]  Resources

## Outcome description – please include information about whether a change in patient management, or prognosis, occurs as a result of the test information:

A change in patient management is expected as a result of the test information.

Financial implications

* + Total cost to Medicare Benefits Schedule and Australian Government budgets.

# Claims

## In terms of health outcomes (comparative benefits and harms), is the proposed technology claimed to be superior, non-inferior or inferior to the comparator(s)? (please select your response)

[x]  Superior

[ ]  Non-inferior

[ ]  Inferior

## Please state what the overall claim is, and provide a rationale:

As per 1593 Ratified PICO, the overall clinical claim is that REGENETEN is associated with superior health outcomes for patients with RCTs through improved efficacy and at least non-inferior safety, if not superior safety, in comparison to treatment with standard surgical repair.

The rationale for this claim are the results from the REGENETEN clinical trial program which demonstrated that patients in the REGENETEN arm experienced significantly lower re-tear rates, significantly lower failure rate at the musculotendinous junction, loser post-operative fatty infiltration, no difference in complications between groups, improvement in function and pain scores (Constant-Murley Shoulder Score and VAS pain score assessments) compared to the control group (standard surgical repair) (35).

## Why would the requestor seek to use the proposed investigative technology rather than the comparator(s)?

REGENETEN is associated with superior health outcomes for patients with RCTs through improved efficacy and at least non-inferior safety, if not superior safety, in comparison to treatment with standard surgical repair.

The results from the REGENETEN clinical trial program demonstrated that patients in the REGENETEN arm experienced significantly lower re-tear rates, significantly lower failure rate at the musculotendinous junction, loser post-operative fatty infiltration, no difference in complications between groups, improvement in function and pain scores (Constant-Murley Shoulder Score and VAS pain score assessments) compared to the control group (standard surgical repair) (35).

## Identify how the proposed technology achieves the intended patient outcomes:

The REGENETEN implant, when used in isolation (partial-thickness tears) or as an adjunct to a mechanical repair (full-thickness tears), provides a porous scaffold for the formation of new tendon-like tissue. REGENETEN supports the body’s natural healing response to facilitate new tendon-like tissue growth and change the course of rotator cuff tear progression. As the newly formed tissue begins to take up more local stress, a natural cell-based remodelling of the extracellular matrix occurs, and the implant is resorbed within six months (28). The load sharing abilities of the new tendon-like tissue decreases the strain in the native tendon to allow for tendon healing and functional gains (29). REGENETEN is positioned arthroscopically, tendon and bone staples secure the scaffold in place while the new tissue is being generated. The procedure is performed under general anaesthesia and may be performed by mini-open surgery (30).

## For some people, compared with the comparator(s), does the test information result in:

**A change in clinical management?** Yes

**A change in health outcome?**  Yes

**Other benefits?** Yes

## Please provide a rationale, and information on other benefits if relevant:

Please refer to the above outcomes

## In terms of the immediate costs of the proposed technology (and immediate cost consequences, such as procedural costs, testing costs etc.), is the proposed technology claimed to be more costly, the same cost or less costly than the comparator? (please select your response)

[ ]  More costly

[x]  Same cost

[ ]  Less costly

## Provide a brief rationale for the claim:

For both patient subpopulations, the Applicant advised that the comparative clinical claim is likely to be superior effectiveness for functional outcomes and similar safety. Therefore, a cost-effectiveness analysis or cost-utility analysis would be appropriate.

# Algorithms

## Preparation for using the health technology

## Define and summarise the clinical management algorithm, including any required tests or healthcare resources, before patients would be eligible for the proposed health technology:

In order to access this treatment, patients should not have responded to conservative (i.e. non-surgical) management, including pain relief (e.g. nonsteroidal anti-inflammatory medication (NSAIDs) ± corticosteroid injections), modified daily activities and physical therapy (e.g. physiotherapy) for at least three months

## Is there any expectation that the clinical management algorithm *before* the health technology is used will change due to the introduction of the proposed health technology?

No

## Describe and explain any differences in the clinical management algorithm prior to the use of the proposed health technology vs. the comparator health technology:

N/A

## Use of the health technology

## Explain what other healthcare resources are used in conjunction with delivering the proposed health technology:

Increased procedure time to implant REGENTEN in subpopulation 2 (FTRCT) by 10 minutes.

## Explain what other healthcare resources are used in conjunction with the comparator health technology:

There are no other healthcare resources in conjunction to the standard repair techniques, using sutures or anchors.

## Describe and explain any differences in the healthcare resources used in conjunction with the proposed health technology vs. the comparator health technology:

A key difference between the intervention and comparator in subpopulation 1 is that bovine BCI can be used without standard repair techniques, using sutures or anchors.

Healthcare system perspective: [specific to each subpopulation]

**Subpopulation 1**

A potential decrease in hospital (operative) resources required with the application of bovine BCI in patients with symptomatic PTRCTs.

Expert opinion and case study reference confirms that the average time to implant the REGENETEN system is 10 minutes (26) and may vary depending on the learning curve of the surgeon. For subpopulation 1 REGENETEN is implanted in phase three of the surgical repair procedure in lieu of implanting suture anchors (as standard surgical repair with sutures or anchors is not required in this population) and thus, there is no incremental procedural time.

**Subpopulation 2**

A potential increase in hospital (operative) resources required with the application of bovine BCI in patients with symptomatic PTRCTs. The Applicant claimed that this is due to both intervention and comparator would receive standard arthroscopic or open rotator cuff surgery using sutures or anchors (phase 3 in this population) and the intervention arm would receive the additional 10 minutes application of bovine BCI surgical procedure, resulting in surgical time of 40-70 minutes vs. standard 30-60 minutes for standard surgical repair without bovine BCI (26, 27, 36) (see Table 5).

Table 5 Description of surgical procedures with use of bovine BCI in both populations

| - | **Subpopulation 1** | **Incremental Procedure time** | **Subpopulation 2** | **Incremental Procedure time** |
| --- | --- | --- | --- | --- |
| Phase 1 | Anaesthesia and skin penetration | - | Anaesthesia and skin penetration | - |
| Phase 2 | Debridement, diagnosis and bursectomy | - | Debridement, diagnosis and bursectomy | - |
| Phase 3 | **Arthroscopic surgical repair with REGENETEN**  | **N/A REGENETEN is****implanted (10 mins) in lieu of suture anchors and thus there is no incremental procedural time** | Standard arthroscopic or mini-open surgical repair (Sutures or anchors)a |  |
| Phase 4 | N/A | N/A | **Arthroscopic surgical repair with REGENETEN** | **10****Minutes (26, 36)** |

Source: Applicant feedback

N/A = not applicable

a As per comparator; refer to comparator section for description of these surgical procedures

## Clinical management after the use of health technology

## Define and summarise the clinical management algorithm, including any required tests or healthcare resources, *after* the use of the proposed health technology:

Post-operative care

Following the procedure (performed arthroscopically or ‘mini-open’ approach), standard pain management measures should be undertaken. The Applicant stated that the postoperative protocol is immediate range of motion as tolerated, with the patient using a sling for comfort. Strengthening can begin once full range of motion has returned.

Specifically, post-operative care in Bokor et al. for patients:

* with symptomatic PTRCTs (subpopulation 1) was: discontinuation of the sling when comfortable (maximum of 1 week); progress from passive-assisted to active motion (under physiotherapy supervision), with no restrictions on arm for 6 weeks (2, 39); and
* with symptomatic FTRCTs (subpopulation 2) a more extensive rehabilitation program was followed: discontinuation of sling during first six weeks; passive-assisted motion for six weeks and progression to active motion beyond six weeks; and after 12 weeks, a gradual resistance program was adopted (1).

## **Define and summarise the clinical management algorithm, including any required tests or healthcare resources, after the use of the comparator health technology:**

As provided in Figure 2, the post-operative rehabilitation algorithm for the comparator health technology includes either:

* improvement
* no improvement: requires further investigation or revision surgery

Note failure of rotator cuff repairs is reportedly 20-40% after primary rotator cuff repairs and is even higher in revision cases (37, 38). Re-tear of a rotator cuff repair has been associated with a multitude of factors including patient age, tear dimensions, and tendon tissue quality (40). A recent study found that re-tears following rotator cuff repair primarily occurred between 6-26 weeks, with a substantial number of re-tears occurring between 12-26 weeks (). With over one-quarter of repairs failing to achieve durable integrity (i.e. re-tears) of the rotator cuff at two years (54), the inability to obtain high healing rates has spurred the investigation of biological options to augment rotator cuff repairs (22) (*e.g. application of bovine BCI in surgical repair of rotator cuff tears*).

## Describe and explain any differences in the healthcare resources used *after* the proposed health technology vs. the comparator health technology:

Healthcare system perspective

A potential decrease in the resources (hospital- and/or community-based services) required for the post-operative management and rehabilitation of patients treated with bovine BCI procedure. Based on expert opinion (39), the Applicant advised patients who receive surgery with bovine BCI may only need one week in a sling with six weeks rehabilitation compared with 6 weeks in a sling and between 6-9 months recovery with standard surgical repair [Application form, p15]. The Applicant-nominated clinical expert advised that many patients do not willingly choose conventional surgery, as it involves a lengthy recovery period during which their activities are restricted. Specifically, resources that could decrease within rehabilitation programs include diagnostic testing (e.g. MRI is performed as standard practice 6 months post-operative if patients have not improved), allied health services (e.g. physiotherapy) and services and/or treatments for pain management (e.g. NSAIDs and/or corticosteroid injections).

A potential decrease in hospital resources (operative) if the application of bovine BCI results in fewer patients requiring subsequent surgical revision, due to clinical failure (I.e. re-tear) of the primary rotator cuff tear procedure. Schlegel et al., (2018) (33) reported that none of the patients with symptomatic PTRCTs repaired using BCI who followed the post-operative rehabilitation protocol, needed any revision surgery through to the 1-year follow-up. Similarly, Bokor et al. (1, 2) reported no tear progression or re-tears were observed during 24-month follow-up. However, in a population with advanced FTRCT disease (large and massive tears), two patients (9%) had clinical failure, with one requiring revision surgery with reverse shoulder arthroplasty, due to progression of patient’s arthritis and further atrophy of rotator cuff (Thon et al 2019 (22)) (see efficacy results for bovine BCI in Table 6 – attached as appendix).

## Insert diagrams demonstrating the clinical management algorithm with and without the proposed health technology:

The Applicant’s current and proposed clinical management algorithm was based on consultation with experts [Application Form, p11], as there are currently no Australian specific guidelines for repair of rotator cuff tears. Specifically, there is no consensus on a single algorithmic treatment approach to patients with a symptomatic PTRCT (2). The place of bovine BCI, performed in addition to arthroscopic surgery (debridement and bursectomy) in subpopulation 1 and in addition to standard arthroscopic or mini-open surgical repair in subpopulation 2 was highlighted in red during the preparation of the PICO confirmation. In addition, downstream options were also added during the preparation of the PICO confirmation. The current and proposed clinical management algorithm for identified population is provided in Figure 2.

The Applicant acknowledges the REBUILD Registry analysis by Bushnell (2021b) which included 31 patients who underwent take-down and repair with bioinductive augmentation in patients with PTRCT (42). The Applicant would like to state that this is not standard of care for patients with PTRCT, as bovine BCI replaces the need for the more invasive take-down and repair approach (utilizing suture anchors); however, the publication by Bushnell had a secondary purpose to “analyse the effect of various demographic, biologic, and surgical risk factors on outcomes— in particular, the performance of IBR with the implant alone in comparison with take-down and repair with implant supplementation in partial-thickness tears”(42). By demonstrating significantly superior patient reported outcomes in the short-term and comparable long term outcomes, rotator cuff repair via IBR replaces the need for the take-down and repair procedure which risks damaging normal tissue and permanently alters the natural anatomic foot print, with a resulting discrepancy in length-tension relationship after repair, this technique may also require prolonged rehabilitation (42).

|  |
| --- |
| *Figure 2 - Current and proposed algorithm for subpopulation 1 (PTRCT) and subpopulation 2 (FTCRT)* |
| Current and proposed algorithm for subpopulation 1 (PTRCT) and subpopulation 2 (FTCRT)  Schematic algorithm |
| Source: Compiled from [Application Form, p21Abbreviations: BCI = bioinductive collagen implant MRI = magnetic resonance imaging; MRA = magnetic resonance arthrography; NSAID= nonsteroidal anti-inflammatory drugs; U/S = ultrasounda 1 patient with a high-grade PTRCT received bovine BCI following a take-down repair (sutures or anchors) in Bokor 2015 (1)b All patients with FTRCTs in Bokor et al 2015 (1) and Thon et al. 2019 (22) received bovine BCI after surgical repair (sutures or anchors)c Applicant stated that after receiving surgery patients are followed up for 3 months as routine practice [ Application form, p15]d Possible investigations could include imaging (MRI), physical therapy sessions, and treatments for pain managemente 2 patients with FTRCTs (large or massive) had clinical failure in Thon et al. 2019 (22), resulting in 1 requiring revision surgery with reverse shoulder arthroplasty, due to progression of arthritis |

**Summary of Evidence**

## Provide one or more recent (published) high quality clinical studies that support use of the proposed health service/technology. At ‘Application Form lodgement’,

|  | **Type of study design** | **Title of journal article or research project**  | **Short description of research** | **Website link to journal article or research** | **Date of publication** |
| --- | --- | --- | --- | --- | --- |
| 1 | Non-randomised, single-arm, single-centre Level IV  | Evidence of healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a collagen implant: a 2-year MRI follow-up (ACTRN12611001082998)  | Repairs of partial-thickness rotator cuff lesions in 13 patients were performed using collagen implant. Evaluated using MRI at 3,6, 12 and 24 months post-operatively. * Significantly improved clinical scores (p=0.01)
* Significant (p<0.0001) new tissue formation by 3 months
* No tear progression at 24 months
 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915456/  | 2016  |
| 2 | Non-randomised, single-arm, single- centre Level IV  | Preliminary investigation of a biological augmentation of rotator cuff repairs using a collagen implant: a 2-year MRI follow-up (ACTRN12611001082998)  | Repairs of full-thickness rotator cuff lesions in 9 patients were performed using collagen implant. Evaluated using MRI at 3,6, 12 and 24 months post-operatively. * Clinical scores improved significantly (p <.001)
* Significant mean tendon thickness increased (p <.0001)
* No re-tears observed during the 24-month follow-up
 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4617212/  | 2015  |
| 3 | Non-randomised, single-arm, retrospective study Level IV  | Histologic Evaluation of Biopsy Specimens Obtained After Rotator Cuff Repair Augmented with a Highly Porous Collagen Implant  | Biopsies of collagen implant/host-tissue constructs from 7 patients undergoing a second arthroscopic procedure after arthroscopic rotator cuff repair augmented with a collagen implant. * increased collagen formation, maturation, and organisation over the surface of the implant at 3 months
* newly generated tissue at 6 months
 | https://www.ncbi.nlm.nih.gov/pubmed/27650821  | 2017  |
| 4 | Non-randomised, single-arm, multi-centre Level IV  | Radiologic and clinical evaluation of a bioabsorbable collagen implant to treat partial thickness tears: a prospective multicentre study  | Repairs of partial-thickness rotator cuff lesions in 33 patients were performed using collagen implant. Evaluated using MRI at 3 and 12 months post-operatively. * Clinical scores improved significantly (p <.0001)
* Mean tendon thickness increased by 2.0 mm (p <.0001)
* No serious adverse events related to the implant
 | https://www.ncbi.nlm.nih.gov/pubmed/29157898  | 2018  |
| 5 | Observational registry study Level IV  | Rotation Medical Bioinductive Implant Database Registry (REBUILD) Registry (NCT02784600)  | Registry of 173 patients with partial (N=90) or full-thickness (N=83) rotator cuff lesions who underwent surgery using collagen implant. Post-operative assessments were performed at 2, 6, 12 weeks and 6 and 12 months. * Both groups experienced statistically significant (p<0.001) improvement in VAS, SANE, VR-12 PCS, ASES and WORC scores
 | https://clinicaltrials.gov/ct2/show/NCT02784600  | 2019  |
| 6 | Non-randomised, single-arm, single-centre Level IV | Evaluation of Healing Rates and Safety With a Bioinductive Collagen Patch for Large and Massive Rotator Cuff Tears: 2-Year Safety and Clinical Outcomes | 23 patients underwent repair of FT large/massive RCT augmentation with REGENTEN. MRI scan used to confirm tendon healing and thickness at minimum 6 months postoperatively, ultrasound used to assess thickness at 3-, 6-, 12-, 24- months.* 96% healing rate via US and MRI
* 0 AEs attributed to REGENETEN
 | https://pubmed.ncbi.nlm.nih.gov/31150274/ | 2019 |
| 7 | Non-randomised, single-arm, single-centre Level IV | Healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a highly-porous collagen implant: a 5-year clinical and MRI follow-up | 11 of original 13 patients examined after 5 years. Constant, ASES and MRI evaluations of tendon integrity and quality were compared to the two-year results.* 73% had no decline in tendon integrity
* Significant improvements from baseline in ASES total score and ASES pain score were sustained to 5 years (p≤0.01)
 | http://www.mltj.online/healing-of-partial-thickness-rotator-cuff-tears-following-arthroscopic-augmentation-with-a-highly-porous-collagen-implant-a-5-year-clinical-and-mri-follow-up/ | 2019 |
| 8 | Non-randomised, single-arm, single-centre Level IV | Bioinductive collagen implants facilitate tendon regeneration in rotator cuff tears | 30 patients (PTRCT & FTRCT) underwent arthroscopic repair and augmentation with REGENETEN. Preoperatively and at 6 and 12 months postoperatively, VAS, ASES, CMS were evaluated.* statistically significant improvements vs pre-operative values in VAS pain score (p=0.003), ASES (p=0.001) and CMS (p=0.001) at 6 months post-operatively, which were sustained at 1 year
 | https://jeo-esska.springeropen.com/articles/10.1186/s40634-022-00495-7 | 2022 |
| 9 | Non-randomised, single-arm, multi-centre Level IV | Isolated bioinductive repair of partial thickness rotator cuff tears using a resorbable bovine collagen implant: Two-year radiologic and clinical outcomes from a prospective multicentre study | 33 patients with PTRCT underwent arthroscopic repair with REGENETEN over the bursal surface of the tendon.* At 2 years, 87% of tears had reduced in size by >50% from pre-operative measurements
* No compliant patient progressed to a full-thickness tear
* Improvements in CMS met or exceeded MCIDs
 | https://www.sciencedirect.com/science/article/abs/pii/S1058274620308946?via%3Dihub | 2021 |
| 10 | Non-randomised, single-arm, multi-centre Level IV | Retear rates and clinical outcomes at 1year after repair of full-thickness rotator cuff tears augmented with a bioinductive collagen implant: a prospective multicenter study | 115 patients with FTRCTs unresponsive to CMM with shoulder pain lasting >3 months underwent augmenting single- or double-row arthroscopic repair of FTRCTs with REGENETEN.* ASES and CMS scores significantly improved between the baseline and 1 year
 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910780/ | 2021 |
| 11 | Non-randomised, single-arm, multi-centre Level IV | Two-year outcomes with a bioinductive collagen implant used in augmentation of arthroscopic repair of full-thickness rotator cuff tears: final results of a prospective multicenter study. | 115 patients underwent augmenting single- or double-row arthroscopic repair of FTRCTs with REGENETEN. * 97.1% surveyed were satisfied with the procedure; 100% of patients surveyed would recommend the procedure to a friend
* >90% of patients had significant post-operative improvements in ASES Shoulder and CMS scores that exceeded respective MCIDs (p<0.001)
 | https://www.sciencedirect.com/science/article/abs/pii/S105827462200547X?via%3Dihub | 2022 |
| 12 | Non-randomised, single-arm, single-centre Level IV | Bio-inductive implant for rotator cuff repair: our experience and technical notes. | 4 patients with RCTs (1x PTRCT, 3x FTRCT) underwent surgical repair with REGENETEN. * no complications were found at 6 weeks follow-up
* Increase in procedure duration by 10 minutes
 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944686/ | 2020 |
| 13 | Non-randomised, single-arm, single-centre Level IV | Collagen-Based Bioinductive Implant for Treatment of Partial Thickness Rotator Cuff Tears | 30 PTRCT patients who previously underwent surgical repair via implantation of REGENETEN over the bursal surface were identified and surveyed.* Increase in mean ASES score
* Decrease in VAS pain from 8.3 pre-operatively to 3.8 (19.1 months)
* Mean patient satisfaction of 7.5/10
* No implant related complications
* Mean tendon thickness significantly increased
 | https://hjdbulletin.org/files/archive/pdfs/BHJD%2078(3)2020%20pp%20195-201%20Dai%20Campbell%20Bloom%20et%20al.pdf | 2020 |
| 14 | Economic analysis | Resorbable Bioinductive Collagen Implant Is Cost Effective in the Treatment of Rotator Cuff Tears | Decision analytic model to compare expected incremental cost and clinical consequences for a cohort of patients with FTRCT.* REGENETEN + conventional RCR results in incremental costs of $232,468 and an additional 18 healed RCTs/100 treated patients over 1 year.
* Estimated ICER = $13,061/healed RCT compared to conventional RCR alone
 | https://www.sciencedirect.com/science/article/pii/S2666061X23000020#:~:text=Results,treated%20patients%20over%201%20year. | 2023 |
| 15 | Retrospective Case Series, registry, multi-centreLevel IV | Patient-Reported Outcomes After Use of a Bioabsorbable Collagen Implant to Treat Partial and Full-Thickness Rotator Cuff Tears | 1 year FU of 173 patients (PTRCT and FTRCT) to assess PROMs at 2, 6, and 12weeks, 6months and 1 year.* PTRCT:
	+ MCIDs achieved in VAS pain from 2 weeks and ASES score from 6 weeks
* FTRCT:
	+ MCIDs achieved in VAS pain from 2 weeks and ASES score from 3 months
 | https://www.sciencedirect.com/science/article/abs/pii/S0749806319301562?via%3Dihub | 2019 |
| 16 | Retrospective Case Series, registry, multi-centreLevel IV | Full-Thickness Rotator Cuff Tears Can Be Safely Treated With a Resorbable Bioinductive Bovine Collagen Implant: One-Year Results of a Prospective, Multicenter Registry | 1 year FU of 192 FTRCT patients augmented with REGENETEN.* At 6 months and 1 year, ASES, SANE, VR-12 PCS and WORC were significantly improved
* Mean duration of post-operative recovery (days): sling time, 36.3; return to driving, 24.0; return to work, 48.4; return to non-overhead sports, 105.4, return to overhead sports, 131.7
 | https://www.arthroscopysportsmedicineandrehabilitation.org/article/S2666-061X(21)00119-X/fulltext | 2021 |
| 17 | Literature review of case studies and registry data, multi-centre,Level V | Regeneten bio-inductive collagen scaffold for rotator cuff tears: indications, technique, clinical outcomes, and review of current literature. | * 92–94% patient satisfaction in PTRCT (2 studies)
* 94–100% healing rate PTRCT (2 studies)
* 89–91% patient satisfaction FTRCT (2 studies)
* 96–100% healing rate FTRCT (2 studies)
* 3.9% reoperation rate (10/251; 5 studies)
* 5.9% failure rate (5 studies)
* 9.9% complication rate (5 studies)
 | https://aoj.amegroups.com/article/view/5816/html#B17 | 2020 |

PTRCTs. Partial Thickness Rotator Cuff Tears; RCTs, Rotator Cuff Tears; RCR, Rotator Cuff Repair; ICER, incremental cost-effectiveness ratio; FU, follow up; MCIDs, minimal clinically important differences; VAS, visual analogue scale; ASES, American Shoulder and Elbow Surgeons

Identify yet-to-be-published research that may have results available in the near future (that could be relevant to your application).

|  | **Type of study design** | **Title of journal article or research project**  | **Short description of research**  | **Website link to journal article or research**  | **Date of publication** |
| --- | --- | --- | --- | --- | --- |
| 1 | Comparative, randomised controlled trial, multi-centre study,Level II | Clinical Trial on the Effect of REGENETEN Bioinductive Implant in the Supraspinatus Tendon Repair. (MALLAMANGUITO)NCT04444076 The Effect on healing rate of theaddition of a bioinductive implant to a rotator cuff repair. | Comparative study of RCR with REGENETEN vs Standard RCR.1-year results from this study (57 patients), show:* Significantly lower re-tear rates in REGENETEN group
* No differences in post-operative complications between groups
* failure rate at the musculotendinous junction significantly lower in REGENETEN group
* Post-operative fatty infiltration was lower in REGENETEN group
 | Journal article not yet published. https://clinicaltrials.gov/ct2/show/NCT04444076Interim results presented at The European Society for Surgery of the Shoulder and Elbow (SECEC) Annual Congress; September 7–9, 2022; Dublin, Ireland. | N/A |
| 2 | Randomised controlled trial, multi-centre study,Level II | Independent RCT by Dr Chamacho-Chacon | 2-year follow-up results | Journal article not yet published and public clinical trial number not available. | N/A |
| 3 | Comparative, randomised controlled trial, multi-centre study,Level II | Use of bio inductive bovine collagen patch augmentation for full thickness cuff tears -12-month follow up resultsof an ongoing prospectiverandomised trial. | Comparative study of RCR with REGENETEN vs Standard RCR.1-year results from this study (56 patients), show:* lower re-tear rates in REGENETEN group
* Improved function and pain scores in REGENETEN group (CMS and VAS pain)
* 3 cases of shoulder stiffness/adhesive capsulitis (2 REGENETEN group, 1 control group)
 | Interim results presented at The European Society for Surgery of the Shoulder and Elbow (SECEC) Annual Congress; September 7–9, 2022; Dublin, Ireland. | N/A |
| 4 | Comparative, randomised controlled trial, multi-centre study,Level II | TSA Subscap RCT Dr CvetanovichIIS |  |  | N/A |
| 5 | Comparative, retrospective, cohort studyLevel III | Australia retrospective return to work comparative study |  |  | N/A |
| 6 |  | Amplitude Registry |  |  | N/A |

PTRCTs. Partial Thickness Rotator Cuff Tears; RCTs, Rotator Cuff Tears; RCR, Rotator Cuff Repair; ICER, incremental cost-effectiveness ratio; FU, follow up; MCIDs, minimal clinically important differences; VAS, visual analogue scale; ASES, American Shoulder and Elbow Surgeons

**References**

1. Bokor DJ, Sonnabend D, Deady L, Cass B, Young A, Van Kampen C, et al. Preliminary investigation of a biological augmentation of rotator cuff repairs using a collagen implant: a 2-year MRI follow-up. 2015;5(3):144.
2. Bokor DJ, Sonnabend D, Deady L, Cass B, Young A, Van Kampen C, et al. Evidence of healing of partial- thickness rotator cuff tears following arthroscopic augmentation with a collagen implant: a 2-year MRI follow-up. 2016;6(1):16.
3. Beaudreuil J, Dhénain M, Coudane H, Mlika-Cabanne NJO, Surgery T, Research. Clinical practice guidelines for the surgical management of rotator cuff tears in adults. 2010;96(2):175-9.
4. Clark JJTJob, volume jsA. Tendons, ligaments, and capsule of the rotator cuff. Gross and microscopic anatomy. 1992;74(5):713-25.
5. Matthewson G, Beach CJ, Nelson AA, Woodmass JM, Ono Y, Boorman RS, et al. Partial thickness rotator cuff tears: current concepts. 2015;2015.
6. New Zealand Guidelines Group. The diagnosis and management of soft tissue shoulder injuries and related disorders. New Zealand: Accident Compensation Corporation. New Zealand; 2004.
7. Bollier M, Shea KJTIOJ. Systematic review: what surgical technique provides the best outcome for symptomatic partial articular-sided rotator cuff tears? 2012;32:164.
8. Ellman HJCo, research r. Diagnosis and treatment of incomplete rotator cuff tears. 1990(254):64-74.
9. Modi CS, Smith CD, Drew SJJIjoss. Partial-thickness articular surface rotator cuff tears in patients over the age of 35: Etiology and intra-articular associations. 2012;6(1):15.
10. Sher JS, Uribe JW, Posada A, Murphy BJ, Zlatkin MBJJ. Abnormal findings on magnetic resonance images of asymptomatic shoulders. 1995;77(1):10-5.
11. Yeo DY, Walton JR, Lam P, Murrell GA. The Relationship Between Intraoperative Tear Dimensions and Postoperative Pain in 1624 Consecutive Arthroscopic Rotator Cuff Repairs. Am J Sports Med. 2017;45(4):788-93.
12. Ardeljan A, Palmer J, Drawbert H, Ardeljan A, Vakharia RM, Roche MW. Partial thickness rotator cuff tears: Patient demographics and surgical trends within a large insurance database. J Orthop. 2020;17:158-61.
13. Yamanaka K, Matsumoto T. The joint side tear of the rotator cuff. A followup study by arthrography. Clin Orthop Relat Res. 1994(304):68-73.
14. Mall NA, Kim HM, Keener JD, Steger-May K, Teefey SA, Middleton WD, et al. Symptomatic progression of asymptomatic rotator cuff tears: a prospective study of clinical and sonographic variables. 2010;92(16):2623
15. Lo IK, Burkhart SSJATJoA, Surgery R. Transtendon arthroscopic repair of partial-thickness, articular surface tears of the rotator cuff. 2004;20(2):214-20
16. Tashjian RZJCism. Epidemiology, natural history, and indications for treatment of rotator cuff tears. 2012;31(4):589-604
17. Washburn III R, Anderson TM, Tokish JMJAt. Arthroscopic rotator cuff augmentation: surgical technique using bovine collagen bioinductive implant. 2017;6(2):e297-e301
18. Sambandam SN, Khanna V, Gul A, Mounasamy VJWjoo. Rotator cuff tears: an evidence based approach. 2015;6(11):902
19. Yamanaka K, Fukuda HJK. Pathological studies of the supraspinatus tendon with reference to incomplete thickness tear. 1987;11(1):98-102.
20. Denkers M, Pletsch K, Boorman R, Hollinshead R, Lo I, editors. Partial thickness rotator cuff tears: observe or operative. Proceedings of the American Academy of Orthopaedic Surgeons Annual Meeting; 2012
21. DeOrio J, Cofield RJJBJSA. Results of a second attempt at surgical repair of a failed initial. 1984;66:563-7
22. Thon SG, O’Malley L, O’Brien MJ, Savoie III FHJTAjosm. Evaluation of Healing Rates and Safety With a Bioinductive Collagen Patch for Large and Massive Rotator Cuff Tears: 2-Year Safety and Clinical Outcomes. 2019:0363546519850795.
23. Morse K, Davis AD, Afra R, Kaye EK, Schepsis A, Voloshin IJTAjosm. Arthroscopic versus mini-open rotator cuff repair: a comprehensive review and meta-analysis. 2008;36(9):1824-8.
24. Huang R, Wang S, Wang Y, Qin X, Sun YJSr. Systematic review of all-arthroscopic versus mini-open repair of rotator cuff tears: A meta-analysis. 2016;6:22857.
25. Oliva F, Piccirilli E, Bossa M, Via AG, Colombo A, Chillemi C, et al. IS Mu. LT-rotator cuff tears guidelines. 2015;5(4):227.
26. Micheloni GM, Salmaso G, Zecchinato G, Giaretta S, Barison E, Momoli A. Bio-inductive implant for rotator cuff repair: our experience and technical notes. Acta Biomed. 2020;91(14-S):e2020004.
27. Personal communication. MSAC Application 1593 - Response from Applicant to Pre PASC Questions. In: Health Do, editor. Brisbane2019.
28. Arnoczky, S. P., Bishai, S. K., Schofield, B., Sigman, S., Bushnell, B. D., Hommen, J. P., & Van Kampen, C. (2017). Histologic evaluation of biopsy specimens obtained after rotator cuff repair augmented with a highly porous collagen implant. Arthroscopy: The Journal of Arthroscopic & Related Surgery, 33(2), 278-283.
29. Rotator cuff injury (2019) Mayo Clinic. Available at: https://www.mayoclinic.org/diseases-conditions/rotator-cuff-injury/diagnosis-treatment/drc-20350231.
30. Bokor, D. J., Sonnabend, D. H., Deady, L., Cass, B., Young, A. A., Van Kampen, C. L., & Arnoczky, S. P. (2019). Healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a highly-porous collagen implant: a 5-year clinical and MRI follow-up. Muscles, Ligaments & Tendons Journal (MLTJ), 9(3).
31. Woods TC, Carroll MJ, Nelson AA, More KD, Berdusco R, Sohmer S, et al. Transtendon rotator-cuff repair of partial-thickness articular surface tears can lead to medial rotator-cuff failure. 2014;5:151.
32. Sheibani-Rad S, Giveans MR, Arnoczky SP, Bedi AJATJoA, Surgery R. Arthroscopic single-row versus double- row rotator cuff repair: a meta-analysis of the randomized clinical trials. 2013;29(2):343-8.
33. Schlegel TF, Abrams JS, Bushnell BD, Brock JL, Ho CP. Radiologic and clinical evaluation of a bioabsorbable collagen implant to treat partial-thickness tears: a prospective multicenter study. Journal of Shoulder and Elbow Surgery. 2018;27(2):242-51.
34. McIntyre, L. F., McMillan, S., Trenhaile, S. W., Bishai, S. K., & Bushnell, B. D. (2021). Full-thickness rotator cuff tears can be safely treated with a resorbable bioinductive bovine collagen implant: one-year results of a prospective, multicenter registry. Arthroscopy, Sports Medicine, and Rehabilitation, 3(5), e1473-e1479.
35. Iban R. Smith & Nephew CAR: Interim Analysis. 2022
36. Andrews S. Statement of Clinical Relevance. In: Smith & Nephew, editor. 2023.
37. Hein J, Reilly JM, Chae J, Maerz T, Anderson K. Retear Rates After Arthroscopic Single-Row, Double-Row, and Suture Bridge Rotator Cuff Repair at a Minimum of 1 Year of Imaging Follow-up: A Systematic Review. Arthroscopy. 2015;31(11):2274-81.
38. Longo UG, Carnevale A, Piergentili I, Berton A, Candela V, Schena E, et al. Retear rates after rotator cuff surgery: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2021;22(1):749.
39. Abrams JS, Arnoczky S, Bokor DJ, Ho CP, Matthews L, Labbe M, et al. Rehabilitation Protocol for REGENETEN partial thickness tears without repair. 2023.
40. Le BT, Wu XL, Lam PH, Murrell GAJTAjosm. Factors predicting rotator cuff retears: an analysis of 1000 consecutive rotator cuff repairs. 2014;42(5):1134-42.
41. Iannotti JP, Deutsch A, Green A, Rudicel S, Christensen J, Marraffino S, et al. Time to failure after rotator cuff repair: a prospective imaging study. 2013;95(11):965-71.
42. Bushnell BD, Bishai SK, Krupp RJ, McMillan S, Schofield BA, Trenhaile SW, et al. Treatment of Partial-Thickness Rotator Cuff Tears With a Resorbable Bioinductive Bovine Collagen Implant: 1-Year Results From a Prospective Multicenter Registry. Orthop J Sports Med. 2021;9(8):23259671211027850
43. ClinicalTrials.gov. Treatment of Partial-Thickness Rotator Cuff Tears (REGEN PUB 2018); NCT03734536: NIH. US National Library of Medicine; 2019 [Available from: <https://clinicaltrials.gov/ct2/show/NCT03734536?term=NCT03734536&rank=1>.]

# Appendix

Table 3 Description of patient populations for bovine BCI in rotator cuff surgical repair

| **Study ID** | **Indication** | **N** | **Study type** | **Selected patient criteria** | **Country** |
| --- | --- | --- | --- | --- | --- |
| **PEER REVIEW** |  |  |  |  |  |
| **Subpopulation 1** | **(PTRCT)**  |  |  |  |  |
| ACTRN12611001082998Bokor et al. (2016)  | Supraspinatus tendonGradeInt: 6 (46%)High: 7 (54%) | 13 | Prospective, OL, NR, single arm, SC. Level IVa | * Patients aged 40-66 years at surgery
* Chronic shoulder pain > 3 months (resistant to analgesics, anti-inflammatory medication, and physical therapy)
* Exclusion criteria: patients with shoulder instability; grade 3 ≥ chondromalacia; or grade 2 ≥ fatty infiltration of supraspinatus. Recent steroid use, insulin-dependent diabetes, heavy smoking, genetic collagen disease, chronic inflammatory disease, and index shoulder with previous cuff surgery. Contraindications: hypersensitivity to collagen
 | Australia |
| Bokor DJ, et al. 2019 | Supraspinatus tendonGradeInt: 6 (54.5%)High: 5 (45.5%) | 11 |
| Schlegel et al. 2018  | Supraspinatus tendonGradeInt.: 12 (36%)High: 21 (64%) | 33 | Prospective, OL, NR, single arm, MC. Level IVa | * Patients aged ≥ 21 years
* Chronic, degenerative, PTRCT involving at least 25% of tendon thickness (Grade II-III) unresponsive to conservative management (pain medication, physical therapy or injections)
* Exclusion criteria: patients with FTRCT, PTRCT caused by acute injury. Patients with shoulder instability; grade 3 ≥ chondromalacia; or grade 2 ≥ fatty infiltration of supraspinatus, severe calcification within index shoulder. Recent steroid use, insulin-dependent diabetes, heavy smoking, genetic collagen disease, chronic inflammatory disease, and index shoulder with previous cuff surgery.
 | US |
| Schlegel TF, et al. 2021 |
| Dai AZ, et al. 2020 | 16 (66.7%) articular-sided5 (20.8%) bursal-sided3 (12.5%) intrasubstance | 24 | Retro, OL, NR, single arm, SC. Level IVa | * Patients with PTRCT who underwent implantation of collagen-based bioinductive implant over bursal surface of rotator cuff
* Exclusion criteria: patients who had an implant placed to augment a standard FTRCT
 | US |
| Bushnell BD, et al. 2021b | Supraspinatus tendonGrade:I: 49II: 101III: 122 | 272 | Prospective registry, OL, NR, MC. Level IVa | * Patients aged ≥ 21 yearsd (understands English)
* Willingness to participate
 | US |
| **Subpopulation 2** | **(FTRCT)**  |  |  |  |  |
| Thon et al. 2019  | * Large (2-tendon): 11 (48%)
* Massive (3-tendon): 12 (52%)
* Revision surgery 16 (70%)
 | 23 | Prospective, OL, NR, single arm, MC.Level IVa | * Patients aged ≥ 30 years
* Large or massive rotator cuff tear > 3cm and retraction of at least 3cm measured on preoperative MRI
* Exclusion criteria: Patients aged < 30 years; extensive prior treatment incl. physical therapy, injections AND/OR anti-inflammatory medication for >6 weeks before surgery; Hamda grade ≥ 3 preoperative rotator cuff arthropathy; Goutallier grade ≥ 3 muscle atrophy, <2-year clinical follow-up and unwilling to complete study protocol
 | US |
| Bushnell BD, et al. 2021a  | * Medium (1-3cm): 66 (57.4%)
* Large (3-5cm): 49 (42.6%)
 | 115 | Prospective, OL, NR, single arm, MC.Level IVa | * Patients aged ≥ 21 yearsmedium (1-3 cm) or large (3-5 cm)101 FTRCTs often including the supraspinatus tendon planned for surgical repair
* Chronic shoulder pain lasting longer than 3 months that was unresponsive to conservative therapy including – but not limited to – pain medication, physical therapy, and injections
 | US |
| Bushnell BD, et al. 2022 |
| McIntyre LF, et al. 2021 | * Small (<1cm): 12 (5.7%)
* Medium (1-3cm): 92 (43.8%)
* Large (3-5cm): 75 (35.7%)
* Massive (>5cm): 31 (14.8%)
 | 192 | Prospective, OL, NR, single arm, MC.Level IVa | * Patients aged ≥ 21 yearse (understands English)
* Willingness to participate
 | US |
| Iban, 2022NCT04444076 | * Medium (1-3cm)
* Large (3-5cm)
 | 124 | Comparative, RCT, MC,Level IIa | * Supraspinatus Full Thickness Tear (+/- infraspinatus)
* <3cm retraction of supraspinatus tendon
* <4cm AP extension (size of rupture)
* Tear was fully reparable
* >18 years
 | Spain |
| **Subpopulations**  | **1 & 2 (mixed)** |  |  |  |  |
| ACTRN12611001082998Bokor et al. (2015)  | FTRCT: 8 (89%)* Medium (1-3cm)

PTRCT: 1 (11%)* High grade (10mm), bursal sided.(converted to FTRCT at surgery)

All supraspinatus tendon. | 9 | Prospective, OL, NR, single arm, SC. Level IVa | * Patients aged 40-66 years at surgery
* Chronic shoulder pain > 3 months (resistant to analgesics, anti-inflammatory medication, and physical therapy)

Exclusion criteria: patients with shoulder instability; grade 3 ≥ chondromalacia; or grade 2 ≥ fatty infiltration of supraspinatus. Recent steroid use, insulin-dependent diabetes, heavy smoking, genetic collagen disease, chronic inflammatory disease, and index shoulder with previous cuff surgery. Contraindications: hypersensitivity to collagen | Australia |
| Arnoczky et al. 2017  | Supraspinatus tendonFTRCT: 5 (71%)* Medium: 3
* Large: 1
* Massive: 1
* Revision surgery: 1

PTRCT: 2 (29%)* High grade: 1
 | 7 | Retro, OL, NR, single arm, SC. Level IVa | * Patients who underwent rotator cuff repair with collagen implant
* No Exclusion criteria
 | US |
| Camacho-Chacon JA, et al. 2022  | Supraspinatus tendonFTRCT: 12* 1 small
* 7 large
* 4 massive

PTRCT: 18* 11 High
* 7 medium
 | 30 | Prospective, OL, NR, single arm, SC.Level IVa | * Patients >18 years
* Diagnosis of partial or total rupture of the rotator cuff with failure of conservative treatment (analgesics, anti-inflammatory medication, and physical therapy) after 6 months
* absence of previous surgeries
* consent for surgical intervention and specific for surgery and the performance of percutaneous biopsy 6 months after surgery
* absence of infectious complications after arthroscopy
 | Spain |
| Micheloni GM, et al. 2020  | Snyder Classification:3 type C-III1 type A-III | 4 | Prospective, OL, NR, single arm, SC.Level IVa |  | Italy |
| McIntyre L, et al. 2019NCT02784600 | PTRCT: 90 (52%)* Grade 1 (<3mm): 15 (16.7%)
* Grade 2 (3-6mm): 34 (37.8%)
* Grade 3 (>6mm): 41 (45.5%)

FTRCT: 83 (48%)* Small (<1cm): 4 (4.8%)
* Medium (1-3 cm): 42 (50.6%)
* Large (3-5 cm): 25 (30.1%)
* Massive (>5 cm) 12 (14.5%)
 | 173 | Observational registry study, MC.Level IVa | * Patients aged ≥ 21 years (understand English)
* Exclusion criteria: hypersensitive to bovine-derived materials
 | US |
| Thon SG, et al. 2020 19 | PTRCT: 136FTRCT: 115 | 251 | SLR of case study dataLevel IVa | * As per included publications:
	+ Bokor et al 2015 (1)
	+ Bokor et al 2016 (2)
	+ Shlegel et al 2018 (33)
	+ Thon et al 2019 (22)
	+ McIntyre et al 2019 (43)
 | US |
| **YET TO BE**  | **COMPLETED** |  |  |  |  |
| **Subpopulation 1** | **(PTRCT)**  |  |  |  |  |
| *REGENETEN.2021.04 IMPACT Study**Interim data Q1 2025, Final 2026* | High grade (>50%) | *158* | RCT, Level IIa | * >18 years old
* Has isolated high-grade (>50% or >6mm, Ellman Grade 3) partial thickness tear of supraspinatus or supraspinatus and infraspinatus. Failed a minimum of 3 months of conservative management for treatment of partial thickness rotator cuff tear.
* Exclusion: Subjects with insufficient tendon tissue for management and protection of tendon injury using isolated REGENETEN treatment. OA grade >2, subjects with prior shoulder surgery on index shoulder, subjects with subscapularis tear requiring repair, subjects requiring concomitant biceps tenodesis/tenotomy, subjects requiring labral fixation or bony defects, glenohumeral joint instability.
 | Global |
| **Subpopulation 2 (FTRCT)** |
| Camacho-Chacon et al. 2022 | FTRCTSmall <1cm) and medium (1-3cm) | *60* | RCT,MC, ,Level IIa | * Supraspinatus full thickness tear, tear pattern did not exceed dimensions of the REGENETEN implant (20x26mm). Patients had intact rotator cable.
* Exclusion: Rheumatologic disease, active steroid use, previous ipsilateral rotator cuff surgery, significant subscapularis tear, post-traumatic tears, tear pattern requiring significant side-to-side tendon repair, large u-shaped tears, intra-articular pathology such as SLAP, bankart or chondral lesions.
 | Spain |
| Ferreira Barros A, et al. 2022 | FTRCTMedium (1-3cm)Large (3-5cm) | *120* | RCT,MC Level IIa | * Supraspinatus full thickness tear, Bateman grade 2-3 (~Cofield medium-large)
* Exclusion: Infraspinatus and/or subscapularis tears
 | Portugal |
| **Subpopulations**  | **1 & 2 (mixed)** |  |  |  |  |
| REBUILD Registry NCT02784600*Completion: Dec 2019* (Results in McIntyre L, et al. 2019, Bushnell 2021b | PTRCT or FTRCT | *483c* | Observational registry study, MC.Level IVa | * Patients aged ≥ 21 years (understand English)
* Exclusion criteria: hypersensitive to bovine-derived materials
 | US |
| Post-market evaluationNCT02200939 | PTRCT or FTRCT supraspinatus | *148* | Prospective,OL, NR, parallel assignment, MC. Level IVa | * Patients aged ≥ 21 years (understand English)
* Medium or large PTRCT OR very small FTCRT
* Chronic shoulder pain > 3 months unresponsive to conservative therapy (pain medication, physical therapy and injections)
* MRI of shoulder within 60 days
* Willing to comply with post-operative rehabilitation
* Exclusion criteria: massive rotator cuff tears (≥5cm), acute rotator cuff tears, previous rotator cuff surgery, patients with shoulder instability; grade 3 ≥ chondromalacia; or grade 2 ≥ fatty infiltration of supraspinatus. Recent steroid use, insulin-dependent diabetes, heavy smoking, genetic collagen disease, history of autoimmune disorders, chronic inflammatory disease, and index shoulder with previous cuff surgery. Contraindications: hypersensitivity to bovine-derived materials
 | US |
| Amplitude Registry (Global incl. Australian patients)f | PTRCT or FTRCT  | *TBD* | RegistryLevel IVa |  | UKHong KongAdditional cites to come:Australia (April 2023)GermanyFranceSpainPortugal |
| Australia retrospective return to work comparative Cost Benefit Analysisf | PTRCT or FTRCT  | *TBD* | Retrospective cost benefit analysisLevel IVa | * Patients >18
* Failure of conservative medical management
* Presenting with PTRCT or FTRCT
 | Australia |

Source: Compiled from Application Form and accessing Clinicaltrials.gov + amended as per ‘Summary of Evidence’ attachment for resubmitted application

Abbreviations: FTRCT = full-thickness rotator cuff tear; MC = multi-centre; NR = non randomised; OA = osteoarthritis; OL = open label; PTRCT = partial-thickness rotator cuff tear; Retro = retrospective; RA = rheumatoid arthritis; SC = single-centre; US = United States; int = intermediate; RCT = randomised controlled trial; UK = United Kingdom

a National Health and Medical Research Council (NHMRC) levels of evidence

b Includes comparator arm with surgical treatment of partial-thickness rotator cuff tears using standard techniques

c Listed as enrolled on Clinicaltrials.gov; Application stated Registry of 173 patients, with PTRCT (n=90) and FTCRT (n=83)

d limited inclusion criteria proposed to better reflect patients encountered in real-world clinical practice

e limited inclusion criteria proposed to better capture the wide breadth of patient and full-thickness tear causes encountered by clinicians

f public references and internal report not yet available, accumulation of data by S+N is ongoing and will be included in resubmitted ADAR.

Table 6 Summary of current clinical evidence for surgical repair with bovine BCI (REGENETEN)

| **Study ID** | **N** | **Study type** | **Key outcomes results** | **Country** |
| --- | --- | --- | --- | --- |
| **PEER REVIEW** |  |  |  |  |
| **Subpopulation 1**  |  | **(PTRCT)** |  |  |
| ACTRN12611001082998Bokor et al. (2016)  | 13 | Prospective, OL, NR, single arm, SC Level IVa | * Significantly improved clinical scores (Constant-Murley and ASES; p=0.001)
* Significant new tissue formation (p<0.0001)
* No tear progression at 24 months
 | Australia |
| Bokor DJ, et al. 2019 | 11 |
| Schlegel et al 2018 [Rotation Medical trial] | 33 | Prospective, OL, NR, single arm, MC Level IVa | * Significantly improved clinical scores (Constant-Murley and ASES; p<0.001)
* Mean tendon thickness increased by 2.0mm (p<0.0001)
* No serious adverse events related to implant
 | US |
| Schlegel TF, et al. 2021 |
| Dai AZ, et al. 2020 | 24 | Retro, OL, NR, single arm, SC. Level IVa | * Mean ASES scores increased significantly from 45.6 preoperatively to 68.1 postoperatively (p = 0.001)
* Mean VAS pain scores decreased significantly from 8.3 preoperatively to 3.8 postoperatively (p < 0.001).
* Mean patient satisfaction level was 7.5
* Tendon thickness at the tear site increased significantly from 5.7 mm preoperatively to 6.5 mm at mean 9.9 months follow-up (p = 0.007).
* There were no implant-related complications.
* One patient suffered a traumatic re-tear 4 months postoperatively
 | US |
| Bushnell BD, et al. 2021b  | 272 | Prospective registry, OL, NR, MC. Level IVa | * By 3 months, all PROs were significantly improved over baseline with the exception of VR-12 PCS, which became significant at 1 year
* Score improvements met or exceeded the MCID at 1 year for 93.1% of patients for ASES, 91.6% for SANE, 33.9% for VR-12 MCS, 80.2% for VR-12 PCS, and 3.3% for WORC
* At 1 year, there was no significant difference in PROs between the IBR and take-down groups, with the exception of the VR12 PCS favoring the IBR group (48.6 vs 44.1; P = .0213).
* at 1 year, patients who had not undergone prior shoulder surgery had significantly superior scores for ASES Pain (0.9 vs 2.9; P < .0001), ASES Function (26.6 vs 21.0; P = .0002), ASES Shoulder (87.7 vs 71.0; P < .0001), and WORC (85.2 vs 67.1; P = .0006).
* no cases of infection or obvious immunologic “rejection” of the implant
 | US |
| **Subpopulation 2** |  | **(FTRCT)** |  |  |
| Thon et al. 2019  | 23 | Prospective, OL, NR, single arm, MC Level IVa | * No adverse events attributed to implant
* Clinical failurec = 2 patients (9%), 1 requiring additional surgery arthroplasty, due to progression of pain and dysfunction
* MRI rotator cuff thickness = 5.13 ±1.06mm
* Mean ASES at final follow-up = 82.87 ±16.68
 | US |
| Bushnell BD, et al. 2021a  | 115 | Prospective, OL, NR, single arm, MC.Level IVa | * . At 1 year, the minimally clinically important difference for ASES and CMS was met by 91.7% (95% CI: 84.9-96.1) and 86.4% (95% CI: 78.2-92.4) of patients, respectively
* Of 9 reported reoperations in the operative shoulder, only 2 were considered potentially related to the collagen implant.
* 13 retears (11.3%) at 3 months and 19 (16.5%) at 1 year
* At 1 year, no visible boundary between the collagen scaffold/new tissue was not observed or could not be determined in all available (100%).
* At 1 year, 110 of 114 patients (96.5%) reported that they “agreed/ strongly agreed” that they were satisfied with surgery and 4 (3.5%) that they “disagreed/strongly disagreed.”
* mean sling time of 38.7 days (SD, 18.3)
* mean of 22 days (SD, 12.45) spent in physical therapy
* mean time to return to work was 44.1 days (SD, 64.8) and to return to normal activities was 124.6 days (SD, 60.6)
 | US |
| Bushnell BD, et al. 2022 | * Between baseline and 2-year follow-up, mean total thickness of the supraspinatus tendon increased by 12.5% for medium tears and by 17.1% for large tears.
* Radiographic re-tear was noted in 7/61 available
* patients (11.5%) with medium tears, and in 14/40 patients (35.0%) with large tears.
* MCID was achieved by >90% of patients with both medium and large tears for both ASES and CMS
* 2 serious adverse events classified by the treating surgeon as being possibly related to the device and/or procedure (1 case of swelling/drainage and 1 case of intermittent pain).
 |
| McIntyre LF, et al. 2021 | 192 | Prospective, OL, NR, single arm, MC.Level IVa | * Statistically significant improvement in outcomes for the SANE, VR-12 PCS, ASES and WORC over 1 year of registry follow-up
* MCID achieved at 1 year for SANE in 84.3% patients (161/191), for VR-12 MCS in 40.3% (77/191), for VR-12 PCS in 78.5% (150/191), for ASES in 90.5% (86/95), and for WORC in 87.2% (116/133).
* Average time in a sling for 188 patients was 36.3 days (SD, 16.8)
* Return to driving occurred after an average of 24.0 days (SD, 25.8) in 135 patients and work after 48.4 days (SD, 52.1) in 128 patients
* Return to nonoverhead athletics averaged 105.4 days (SD, 77.2) in 71 patients and overhead athletics 131.7 days (SD, 77.3) in 42 patients
* Total number of physical therapy visits among 144 patients averaged 21.8 (SD, 16.2).
* Twenty patients (10.4%) experienced serious complications, including 18 (9.4%) who underwent revision surgeries
 | US |
| Ruiz Iban, 2022NCT04444076 | 57 | Comparative, RCT, MC,Level IIa | * Interim results:
* tendon retears (Sugaya >3) were present in 25% of control patients and 3.5% of REGENETEN patients
* the tendon thickness in non-retear patients was not yet significantly different between groups in this interim report
* 79% of REGENETEN patients had a Sugaya Classification ≤II compared to 46% of patients without REGENETEN.
* There were no additional post-operative complications in the REGENETEN group compared to the control group.
 | Spain |
| Barros | 56 | Comparative RCT, Level II a | * Interim results:
* REGENETEN group: Constant Score average was 49 pre-op, at 3 months was 70, at 6 months was 86, and at 12 months was 89.
* Control group: Constant score average was 52 pre-op, 62 at 3 months, 78 at 6 months and 82 at 12 months.
* REGENETEN VAS pain average was 7.5 pre-op, 2.9 at 3 months, 1.5 at 6 months, 0.7 at 12 months.
* Control VAS pain average was 7.2 pre-op, 4.5 at 3 months, 2.1 at 6 months, 1 at 12 months.
* In the REGENETEN group there were 2 re-ruptures (7%) and 2 adhesive capsulitis. In the Control group there were 4 re-ruptures (13%) and 1 adhesive capsulitis.
 |  |
| **Subpopulations 1 & 2** |  | **(mixed)** |  |  |
| ACTRN12611001082998Bokor et al. (2015)  | 9 | Prospective, OL, NR, single arm, SC Level IVa | * Significantly improved clinical scores (Constant-Murley and ASES; p<0.01)
* Significant mean tendon thickness increased (p<0.01)
* No re-tears observed during 24-month follow-up
 | Australia |
| Arnoczky 2017  | 7 | Retro, OL, NR, single arm, SC Level IVa | Biopsy related outcomes:* Increased collagen formation, maturation and organisation
* Newly generated tissue at 6 monthb
 | US |
| Camacho-Chacon JA, et al. 2022  | 30 | Prospective, OL, NR, single arm, SC.Level IVa | * VAS score improved significantly (P = 0.003), from 7.23 ± 0.77 at the beginning to 0.57 ± 1.13 at six months and 0.27 ± 0.94 at one year
* ASES and Constant scores also improved significantly from 48.03 ± 1.18 to 85.93 ± 7.25 at six months and 87.80 ± 7.00 at one year (P = 0.001) and from 58.60 ± 1.61 to 85.37 ± 6.51 at six months and 90.23 ± 5.88 at one year (P = 0.001), respectively.
* FTRCT: At six months after surgery, there was a significant increase (P = 0.001) in the induction of new tissue of the rotator cuff, going from a mean preoperative thickness in partial tears of 4.18 ± 0.29 mm to 6.02 ± 0.29 mm with an average increase in tendon thickness of 1.84 ± 0.29 mm.
* 0 re-ruptures
 | Spain |
| Micheloni GM, et al. 2020  | 4 | Prospective, OL, NR, single arm, SC.Level IVa | * No complications occurred at 6 months follow-up
 | Italy |
| McIntyre L, et al. 2019NCT02784600 | 173 | Observational registry study, MC.Level IVa | PTRCT: * statistically significant improvement in outcomes for VAS, SANE, VR12 physical component,ASES, and WORC over 12 months of study follow-up (P < .05).
* average time in a sling was 10.6 days for those without biceps surgery and 27.7 days for patients who underwent concomitant tenodesis
* Patients returned to driving in an average of 14.6 days, and to work, in 37.3 days (9.4 days for sedentary jobs and 72.9 for physical jobs).
* Return to athletics averaged 65.6 days, with return to overhead athletics at 117.9 days.
* Patients used opioid medicines for pain control for an average of 18.3 days.
* The total number of PT visits averaged 20.6
 | US |
| Thon SG, et al. 2020 | 251 | SLR of case study dataLevel IVa | * As per included publications:
	+ Bokor et al 2015
	+ Bokor et al 2016
	+ Shlegel et al 2018
	+ Thon et al 2019
	+ McIntyre et al 2019
 | US |

Source: pp6-7 of Application Form and Thon et al. 2019 – New publications added

Abbreviations: ASES = American Shoulder and Elbow Surgeons; FTRCT = full-thickness rotator cuff tear; MC = multi-centre; MRI = magnetic resonance imaging; NR = non randomised; OL = open label; PTRCT = partial-thickness rotator cuff tear; Retro = retrospective; RA = rheumatoid arthritis; SC = single-centre; US = United States; int = intermediate; med = medium; SANE = Single Assessment Numeric Value VR-12 = Veterans RAND 12 Item Health Survey; WORC = Western Ontario Rotator Cuff Index; VAS = visual analogue scale; SLR = Systematic literature review; MCID = Minimal clinically important difference; MCS = Mental Component Score; PCS; Physical Component Score

a National Health and Medical Research Council (NHMRC) levels of evidence

b Implant generated host tissue rapidly matured into tendon tissue

c Was defined as lack of healing on either imaging modality (US and/or MRI) or the need for additional surgical procedures to be performed on the same shoulder during the study period, including conversion to reverse total shoulder arthroplasty.

1. Note ‘tendinitis’ implies a pathology that is not strictly correct. Instead, one should use tendinosis, which is not an inflammatory disorder. Tendinosis (tendinitis) is caused by collagen fibre fatigue and usually develops from repetitive activity at, or above, shoulder height (NZGG 2004; 6) [↑](#footnote-ref-2)
2. Non-surgical repair or debridement includes several procedures: acromioplasty, subacromial bursectomy, smoothing of tendon lesions, excision of the coraco-acromial ligament, tenotomy or tenodesis of the long head of the biceps brachii, and procedures on the acromioclavicular joint (Beaudreuil 2010) (3) [↑](#footnote-ref-3)
3. Double-row techniques increase costs in terms of materials and time of the operating room (Olivia 2015) (26) [↑](#footnote-ref-4)